UNSPSC 51241124: Pirnabin or pirnabine

This classification denotes an anti-glaucoma agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S3FHL03F60. European Medicines Agency schedules Pirnabin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09926MIG. Pirnabin generally arises in the molecular formula C19H24O3.

The term PIRNABIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) PIRNABIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Pirnabin or pirnabine bears US NLM identifiers UMLS ID C3272437 and NCI Concept Code C95917. SMILES: O1C(C2=C(CC(CC2)C)C2C1CC(CC2OC(=O)C)C)(C)C.

UNSPSC 51241124 Pirnabin or pirnabine, a Commodity code, addresses procurement of this antiviral pharmaceutical agent by state and local health departments, correctional facilities, and public hospitals. The code covers acquisition of pirnabin (also known as pirnabine) for treatment of viral infections in patient populations served by public health systems. State and local buyers source this medication through standard pharmaceutical procurement channels, typically as part of formulary management or outbreak response protocols. Issuing bodies include state departments of health, county health departments, municipal hospitals, and state correctional departments that maintain formularies or emergency stockpiles.

The source provides no recent state and local contract opportunities tagged under this code, limiting visibility into current geographic concentration or representative solicitation activity. Without posted RFPs, RFQs, IBFs, or ITBs in the available record, characterization of active buyer jurisdictions, response timelines, or current procurement volume is not supported. Firms monitoring pharmaceutical procurement under this code should track state health department notices and county correctional facility solicitations for any emergence of pirnabin acquisition activity.